Daniel D Shapiro1, Miriam Harel2, Fernando Ferrer2, Patrick H McKenna3. 1. Division of Pediatric Urology, Department of Urology, University of Wisconsin School of Medicine and Public Health, 3217 MFCB, 1685 Highland Ave, Madison, WI, 53705-2281, USA. 2. Division of Urology, Department of Surgery, Connecticut Children's Medical Center, Hartford, CT, USA. 3. Division of Pediatric Urology, Department of Urology, University of Wisconsin School of Medicine and Public Health, 3217 MFCB, 1685 Highland Ave, Madison, WI, 53705-2281, USA. mckenna@urology.wisc.edu.
Abstract
OBJECTIVE: Pediatric genitourinary rhabdomyosarcoma (RMS) accounts for 25 % of all pediatric soft tissue sarcomas. The treatment of these tumors has shifted over time from debilitating radical exenteration to organ-sparing techniques using multimodal therapy. Our review aims to summarize recent relevant literature regarding the current treatment practices of pediatric genitourinary RMS and how these practices have shifted over time. METHODS: PubMed database search was utilized to identify relevant literature from 1997 to 2015 relating to the treatment of pediatric genitourinary RMS with emphasis on organ preservation and maintaining organ function. RESULTS: A total of 31 articles from 1997 through 2015 were identified relating to current management concepts in pediatric genitourinary sarcomas. Relevant articles were reviewed in detail and discussed. CONCLUSION: The treatment of pediatric genitourinary RMS has shifted from debilitating pelvic exenteration to a multimodal treatment approach involving surgery, chemotherapy, and radiation therapy in an effort to preserve genitourinary organs and reduce treatment morbidity. Continued research is required to improve post-treatment organ function. Further studies utilizing objective urodynamic evaluation are necessary to better characterize bladder function after treatment for RMS. Exciting recent developments in RMS research of fusion proteins that induce cell transformation and inhibit apoptosis and myogenic differentiation may result in future management changes to treatment protocols.
OBJECTIVE:Pediatric genitourinary rhabdomyosarcoma (RMS) accounts for 25 % of all pediatric soft tissue sarcomas. The treatment of these tumors has shifted over time from debilitating radical exenteration to organ-sparing techniques using multimodal therapy. Our review aims to summarize recent relevant literature regarding the current treatment practices of pediatric genitourinary RMS and how these practices have shifted over time. METHODS: PubMed database search was utilized to identify relevant literature from 1997 to 2015 relating to the treatment of pediatric genitourinary RMS with emphasis on organ preservation and maintaining organ function. RESULTS: A total of 31 articles from 1997 through 2015 were identified relating to current management concepts in pediatric genitourinary sarcomas. Relevant articles were reviewed in detail and discussed. CONCLUSION: The treatment of pediatric genitourinary RMS has shifted from debilitating pelvic exenteration to a multimodal treatment approach involving surgery, chemotherapy, and radiation therapy in an effort to preserve genitourinary organs and reduce treatment morbidity. Continued research is required to improve post-treatment organ function. Further studies utilizing objective urodynamic evaluation are necessary to better characterize bladder function after treatment for RMS. Exciting recent developments in RMS research of fusion proteins that induce cell transformation and inhibit apoptosis and myogenic differentiation may result in future management changes to treatment protocols.
Entities:
Keywords:
Chemotherapy; Genitourinary rhabdomyosarcoma; Organ sparing; Pediatric urology; Radiation
Authors: David A Rodeberg; James R Anderson; Carola A Arndt; Fernando A Ferrer; Richard Beverly Raney; Meriel E Jenney; Ines B Brecht; Ewa Koscielniak; Modesto Carli; Gianni Bisogno; Odile Oberlin; Annie Rey; Fred Ullrich; Michael C G Stevens; William H Meyer Journal: Int J Cancer Date: 2011-03-01 Impact factor: 7.396
Authors: Frank Heinzelmann; Daniela Thorwarth; Ulf Lamprecht; Theodor W Kaulich; Jörg Fuchs; Guido Seitz; Martin Ebinger; Rupert Handgretinger; Michael Bamberg; Martin Weinmann Journal: Strahlenther Onkol Date: 2011-10-29 Impact factor: 3.621
Authors: David O Walterhouse; Jane L Meza; John C Breneman; Sarah S Donaldson; Andrea Hayes-Jordan; Alberto S Pappo; Carola Arndt; R Beverly Raney; William H Meyer; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2011-02-04 Impact factor: 3.167
Authors: Chi Lin; Sarah S Donaldson; Jane L Meza; James R Anderson; Elizabeth R Lyden; Christopher K Brown; Karen Morano; Fran Laurie; Carola A Arndt; Charles A Enke; John C Breneman Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-04 Impact factor: 7.038
Authors: N Galili; R J Davis; W J Fredericks; S Mukhopadhyay; F J Rauscher; B S Emanuel; G Rovera; F G Barr Journal: Nat Genet Date: 1993-11 Impact factor: 38.330